Patents by Inventor James Strong

James Strong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10253964
    Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.
    Type: Grant
    Filed: July 25, 2016
    Date of Patent: April 9, 2019
    Assignee: Integra LifeSciences Corporation
    Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
  • Publication number: 20160334092
    Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.
    Type: Application
    Filed: July 25, 2016
    Publication date: November 17, 2016
    Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
  • Patent number: 9400101
    Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.
    Type: Grant
    Filed: November 25, 2014
    Date of Patent: July 26, 2016
    Assignee: Integra LifeSciences Corporation
    Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
  • Publication number: 20150153035
    Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.
    Type: Application
    Filed: November 25, 2014
    Publication date: June 4, 2015
    Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. A. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
  • Patent number: 8899774
    Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.
    Type: Grant
    Filed: March 22, 2011
    Date of Patent: December 2, 2014
    Assignee: Integra Lifesciences Corporation
    Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
  • Patent number: 8709443
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: November 2, 2011
    Date of Patent: April 29, 2014
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20120141426
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Application
    Filed: November 2, 2011
    Publication date: June 7, 2012
    Applicant: ONCOLYTICS BIOTECH INC.
    Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20120120635
    Abstract: Wearable headlight devices and related methods are provided and can include a luminaire that can include a housing having a luminaire vent therein for receiving cooling air and a light source contained within the housing. An air moving device can be located outside of the luminaire for facilitating cooling air intake through the luminaire vent. An exhaust tube can be connected to the luminaire and the air moving device to facilitate air flow of the cooling air between the luminaire and the air moving device.
    Type: Application
    Filed: March 22, 2011
    Publication date: May 17, 2012
    Inventors: James Strong, Richard A. Tamburrino, John M. Ryan, Roger W. Leseberg, Ervin Goldfain, David M. Babson, David Stephens, Angelo Martellaro
  • Patent number: 8071087
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: July 22, 2010
    Date of Patent: December 6, 2011
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Patent number: 8066985
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: November 25, 2008
    Date of Patent: November 29, 2011
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20110014155
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Application
    Filed: July 22, 2010
    Publication date: January 20, 2011
    Applicant: ONCOLYTICS BIOTECH INC.
    Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20090117082
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Application
    Filed: November 25, 2008
    Publication date: May 7, 2009
    Applicant: ONCOLYTICS BIOTECH INC.
    Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20090110665
    Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Application
    Filed: November 3, 2008
    Publication date: April 30, 2009
    Applicant: ONCOLYTICS BIOTECH INC.
    Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20090098089
    Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Application
    Filed: October 16, 2008
    Publication date: April 16, 2009
    Applicant: ONCOLYTICS BIOTECH INC.
    Inventors: Patrick W.K. Lee, James Strong, Matthew C. Coffey
  • Patent number: 7476382
    Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: April 30, 2004
    Date of Patent: January 13, 2009
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Patent number: 7374752
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: August 11, 2004
    Date of Patent: May 20, 2008
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20080026048
    Abstract: Methods for treating proliferative disorders, by administering reovirus to a Ras-mediated proliferative disorder, are disclosed. The reovirus is administered so that it ultimately directly contacts ras-mediated proliferating cells. Proliferative disorders include but are not limited to neoplasms. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, serotype 1 (e.g., strain Lang), serotype 2 (e.g., strain Jones), serotype 3 (e.g., strain Dearing or strain Abney), as well as other serotypes or strains of reovirus can be used. Combinations of more than one type and/or strain of reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Application
    Filed: May 30, 2007
    Publication date: January 31, 2008
    Applicant: Oncolytics Biotech Inc.
    Inventors: Patrick Lee, James Strong, Matthew Coffey
  • Patent number: 7300650
    Abstract: Methods for treating neoplasia, by administering reovirus to a Ras-mediated neoplasm, and use of reovirus for manufacture of a medicament for the treatment of neoplasia, are disclosed. The reovirus is administered so that it ultimately directly contacts cells of the neoplasm. Human reovirus, non-human mammalian reovirus, and/or avian reovirus can be used. If the reovirus is human reovirus, type 1 (e.g., strain Lang), type 2 (e.g., strain Jones), type 3 (e.g., strain Dearing or strain Abney), as well as other sterotypes or strains of reovirus can be used. Combinations of more than one type and/or strain or reovirus can be used, as can reovirus from different species of animal. Either solid neoplasms or hematopoietic neoplasms can be treated.
    Type: Grant
    Filed: April 1, 2003
    Date of Patent: November 27, 2007
    Assignee: Oncolytics Biotech Inc.
    Inventors: Patrick W. K. Lee, James Strong, Matthew C. Coffey
  • Publication number: 20060164781
    Abstract: An electrical apparatus of an electric distribution power system includes an electrical device having a high voltage electrical terminal that may be energized, an exterior insulating housing, and an insulator. The exterior insulating housing surrounds and insulates the electrical device, and includes an opening through which the high voltage electrical terminal protrudes such that at least a portion of the high voltage electrical terminal is external to the exterior insulating housing. The insulator covers the electrical terminal and is attached to the exterior insulating housing such that no current flow path is provided through an interface between the insulator and the exterior insulating housing.
    Type: Application
    Filed: January 25, 2006
    Publication date: July 27, 2006
    Inventors: James Strong, David Miller, Jonathan Woodworth
  • Publication number: 20060129058
    Abstract: A system for receiving at least one electromyogram signal representing physiological activity in a quadruped. The system may comprise a first probe and a wireless receiver in wireless communication with the first probe. Also, an electromyogram device for determining a neuromuscular balance of a quadruped. The device may comprise a first probe and a second probe. The device may also comprise a processor in communication with the first probe and the second probe. The processor may be configured to compare a first electromyogram signal captured from the first probe and a second electromyogram signal captured from the second probe. Additional embodiments include an electrode for receiving an electromyogram signal representing physiological activity in a quadruped and a method for analyzing the physiology of a quadruped.
    Type: Application
    Filed: December 13, 2004
    Publication date: June 15, 2006
    Inventors: James Strong, George Power, Errin Miller